- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Royalty bestows Zenas with $300M deal to push autoimmune asset across FDA finish line | 1 | FierceBiotech | ||
| Di | Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab | 257 | AFX News | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) and Zenas BioPharma, Inc. (ZBIO) Tuesday announced that Royalty Pharma will provide up to $300 million in exchange for a royalty on sales of... ► Artikel lesen | |
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Di | Zenas BioPharma and Royalty Pharma enter into Obexelimab funding agreement for $300M | 2 | Seeking Alpha | ||
| Di | Royalty Pharma plc: Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million | 322 | GlobeNewswire (Europe) | Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab... ► Artikel lesen | |
| Di | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Zenas BioPharma reports Q2 results | 1 | Seeking Alpha | ||
| 12.08. | Zenas BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.08. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | 99 | GlobeNewswire (Europe) | - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis... ► Artikel lesen | |
| 10.07. | Citi reiterates Buy rating on Zenas Biopharma stock with $27 price target | 3 | Investing.com | ||
| 03.07. | Morgan Stanley assumes coverage on Zenas Biopharma stock with Overweight rating | 1 | Investing.com | ||
| 03.07. | Morgan Stanley nimmt Zenas Biopharma-Aktie mit Übergewichtung in Beobachtung auf | 4 | Investing.com Deutsch | ||
| 20.06. | Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 143 | GlobeNewswire (Europe) | WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in... ► Artikel lesen | |
| 12.06. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.05. | Zenas BioPharma, Inc. GAAP EPS of -$0.80, revenue of $10M | 1 | Seeking Alpha | ||
| 15.05. | Zenas BioPharma May 2025 slides: key data readouts expected by year-end | 1 | Investing.com | ||
| 15.05. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 245,10 | -0,51 % | Amgen investiert über 600 Millionen Dollar in Innovationszentrum | Der US-Biotechkonzern Amgen will an seinem Hauptsitz im kalifornischen Thousand Oaks ein neues Zentrum für Wissenschaft und Innovation errichten. Für das Projekt sind Investitionen von mehr als 600... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 496,10 | -0,02 % | How Is Regeneron's Stock Performance Compared to Other Pharma Stocks? | ||
| BIOMARIN PHARMACEUTICAL | 52,00 | +2,44 % | Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2 | WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) announced a profit for its second quarter that Increases, from last yearThe company's earnings totaled $240.53 million, or $1.23 per... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 22,010 | -0,32 % | Novartis erhält Lizenzrechte für Parkinson-Behandlung von Arrowhead | DJ Novartis erhält Lizenzrechte für Parkinson-Behandlung von Arrowhead
Von Nicholas G. Miller
DOW JONES--Novartis hat einen potenziell milliardenschweren Deal für eine Parkinson-Behandlung... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM | 25,080 | -0,16 % | Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi | STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049... ► Artikel lesen | |
| INSMED | 124,00 | -0,80 % | Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It | ||
| SCHOLAR ROCK | 27,800 | -2,11 % | Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD | ||
| PROQR THERAPEUTICS | 1,950 | -1,12 % | ProQR Therapeutics N.V.: ProQR Announces Second Quarter 2025 Operating and Financial Results | Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 29,000 | +0,69 % | Crinetics Pharmaceuticals, Inc.: Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) | SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 2,455 | 0,00 % | Ventyx Biosciences, Inc.: Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease | The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson's disease CSF and plasma exposures reinforce VTX3232's potential as a once-daily... ► Artikel lesen | |
| THERATECHNOLOGIES | 2,680 | -0,74 % | Theratechnologies Inc (2): Theratechnologies shareholders urged to support FP deal | ||
| ENSYSCE BIOSCIENCES | 2,080 | 0,00 % | Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025 | ~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~~ Ensysce Biopharma Leader to Deliver... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 34,280 | 0,00 % | Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA? | ||
| TEVOGEN BIO | 0,736 | -3,92 % | Tevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure | WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 28,860 | 0,00 % | Mineralys Therapeutics prices upsized $250M stock offering |
Das Unternehmen ZENAS BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 17,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.